Group 1: Overview of China's Biomanufacturing Industry - The value added by the biomanufacturing sector accounts for over 7% of China's GDP [4] - China ranks second globally in the number of CAR-T cell therapy research centers and the number of biopharmaceuticals under research [1][4] - The biopharmaceutical market in China has surpassed 1.1 trillion yuan, with a significant number of innovative drugs and research pipelines [5] Group 2: Innovations and Developments - The "National Innovation Drug Insight System" was launched to enhance the efficiency of innovative drug development and address industry challenges [7] - The Hubei Pathology Big Database has reached 170,000 high-precision digital slices, positioning it as the second largest globally [6] - The global CAR-T clinical research centers have increased by 60% from 2020 to 2024, with China contributing 388 centers [5] Group 3: Market Growth and Future Projections - The global biomanufacturing market is projected to grow significantly, with the biobased chemicals market expected to reach $125.23 billion by 2029 [8] - China's biomanufacturing sector is positioned as a new engine for economic growth, supported by national policies and strategic planning [8] - The biotechnological innovations in agriculture, such as genetically modified crops, are set to enter the industrialization demonstration phase in 2024 [9]

为生命健康产业发展注入"硬核动能" 此次鼓楼区与南京师范大学的深度合作，是"强强联合"的关键落子。南京师范大学党委副书记、校长华桂宏表示，南师大作为国家"双一流"高校，今年新 增"微生物改造技术"等2个全国重点实验室，叠加"江苏省合成生物技术工程研究中心"等平台优势，在合成生物学、基因编辑领域的科研实力，与鼓楼的 临床资源、产业空间、政策保障形成完美互补，为生命健康产业发展注入"硬核动能"。 值得一提的是，中国工程院院士、南京师范大学副校长黄和将担任智能生物制造创新中心管委会主任，并将带领团队聚焦生物制造前沿领域，依托新科学 与新技术，推动创新中心打造成为合成生物学科研高地，为生命健康产业集群发展提供有力支撑。仪式现场，黄和院士还为微康益生菌、纽邦生物、迪必 尔生物工程、北极光等企业负责人颁发智能生物制造创新中心产业顾问聘书，邀请行业力量共促产业发展。 校企地联动赋能产业，由南京市鼓楼区政府与南京师范大学共建的智能生物制造创新中心启动仪式，在南京幕府智谷成功举办。这也意味着鼓楼生命健康 产业发展按下了"加速键"。 现场一批项目签约 当天现场签约的一批项目则将进一步覆盖细胞库建设、创新药筛选、生物芯片研发等关键 ...

Core Insights - The article highlights the ongoing construction and development of major industrial projects in Nanjing, showcasing the city's economic growth and industrial transformation [1][9][18] Group 1: Major Projects Overview - The total investment for the Mufu Zhigu project is approximately 2.7 billion yuan, with the first phase already housing around 160 companies [3] - The Nanjing Huamao Center project has a total investment of about 8 billion yuan and includes a shopping center, commercial street, and high-end office buildings, with over 30,000 square meters of office space already leased [8] - The State Grid Jiangsu Electric Power New Industry Headquarters Base is under construction and is expected to be completed by the end of 2029 [7][12] Group 2: Industry Impact - The Mufu Zhigu Digital Economy Headquarters aims to create an industrial cluster focused on legal and artificial intelligence sectors [10] - The Smart Biological Manufacturing Innovation Center is set to enhance the synthetic biology field, with several companies already established within the center [11] - The State Grid project is projected to generate an annual output value of 10 billion yuan, integrating smart grid services and new information technologies [15] Group 3: Government Support and Investment Progress - Nanjing's government has implemented measures to optimize service mechanisms for major projects, ensuring efficient problem-solving and support for construction [17] - As of July, the investment progress for 54 provincial major projects reached 67.7%, while 500 municipal major projects achieved 67.1% [17]

Core Insights - The project involves a collaboration between Kailu County and Anhui Fengyuan Group to establish a green zero-carbon bio-manufacturing industrial base [1] - The total investment for the project is 15.5 billion yuan, covering three main sectors: amino acid products, bio-materials, and bio-energy [1] - Upon full production, the project is expected to generate annual sales revenue of approximately 26 billion yuan, with profits of around 3 billion yuan and create about 3,500 jobs [1] Company Overview - Anhui Fengyuan Group is primarily engaged in the research and industrialization of bio-chemicals, bio-pharmaceuticals, bio-materials, and bio-energy [1] - The company is recognized as a national innovative high-tech enterprise [1] - In the field of bio-manufacturing, the company has developed first-generation bio-manufacturing technology using starch sugar as raw material and second-generation technology using straw for sugar production [1]

Core Viewpoint - The article discusses the innovative research on L-methionine synthesis through engineered enzymes, highlighting advancements in enzyme stability and activity, which are crucial for industrial applications in various sectors such as feed, pharmaceuticals, and food [3][4][10]. Group 1: Enzyme Engineering and Research Findings - L-methionine is an essential amino acid with significant applications in feed, pharmaceuticals, and food industries, making its efficient biosynthesis a research focus in biotechnology [3]. - The research team developed a fermentation-enzyme synthesis route for L-methionine, utilizing a high-efficiency cell factory to produce the precursor O-succinyl-L-homoserine (OSH) [3][4]. - A novel strategy called "dynamic network rigidification-local flexibility regulation" was proposed to enhance enzyme activity and stability, addressing the long-standing "activity-stability trade-off" in protein engineering [3][4]. Group 2: Key Experimental Results - The study identified 20 potential mutation sites in the enzyme O-succinyl-L-homoserine mercaptotransferase (CvMetZ) through consensus sequence analysis, leading to beneficial mutations such as T59I and A241T, which improved half-life and enzyme activity significantly [4][5]. - The half-life of the T59I mutant increased from 3.3 hours to 9.8 hours, with a 28% increase in enzyme activity, while A241T achieved a half-life of 11.2 hours and a 25% activity increase [4][9]. - The combination of multiple mutations resulted in a triple mutant (T59I/T119Y/A241T) that exhibited a half-life of 20.6 hours and a 36% increase in enzyme activity, demonstrating the effectiveness of the engineered design [8][9]. Group 3: Industrial Application and Cost Efficiency - The modified enzymes were subjected to immobilization studies, achieving high immobilization efficiency and activity recovery, with over 90% activity retained after the first 10 batches and over 60% after 30 batches [10]. - The fermentation enzyme method for L-methionine synthesis demonstrated a yield of 92.8% using over 100 g/L of O-succinyl-L-homoserine as a substrate, providing critical data for large-scale production [10].

Core Insights - The "Meng-Yue Pioneer" Cup Technology Achievement Transformation Competition was held in Hohhot, focusing on talent cooperation and innovation between Inner Mongolia and Guangdong [1][2] - The competition attracted over 150 participants from universities, research institutes, and enterprises, showcasing 13 projects aligned with Inner Mongolia's key industrial clusters [2][3] Group 1: Competition Overview - The competition was launched in June to enhance technology exchange and achievement transformation between Inner Mongolia and Guangdong, receiving participation from over 70 universities and high-tech enterprises, with a total of 95 projects submitted [2] - The selected projects cover key areas such as new energy, new materials, biomanufacturing, digital economy, and low-altitude economy, aligning with Inner Mongolia's strategic development goals [2][3] Group 2: Strategic Goals and Support - The event aims to promote the "Technology Prosperity in Inner Mongolia" strategy, enhancing regional innovation capabilities and industrial competitiveness through deep integration of innovation and industry chains [3] - The competition provides follow-up services such as investment matching, incubation, and entrepreneurial guidance, supported by the Guangdong University Technology Achievement Transformation Center [3][4] Group 3: Policy and Collaboration Initiatives - The event marked the launch of a talent cooperation mechanism between Inner Mongolia and Guangdong, with detailed policy support for project implementation, including talent introduction incentives and research funding [4] - The competition is co-hosted by the Inner Mongolia government and the Inner Mongolia Academy of Sciences, aiming to create a platform for connecting key industries in Inner Mongolia with innovative resources from Guangdong [4]

Group 1 - The city government emphasizes the importance of project promotion and investment as key drivers for economic performance, aiming for high-quality development [1][3] - A total of 160 major projects have been arranged in Gulou District this year, with a total investment of 191.5 billion yuan, focusing on technology innovation, productive services, and social welfare [2] - The establishment of the Smart Bio-Manufacturing Innovation Center in collaboration with Nanjing Normal University aims to enhance innovation in the synthetic biology field and advance the life health industry chain [2] Group 2 - The National Grid Jiangsu Electric Power Headquarters project plans to integrate four major industrial clusters, with completion expected by the end of 2029 [2] - The Nanjing Huamao Center, with a total construction area of 440,000 square meters, aims to create a comprehensive business and office complex to upgrade the Central Road-Xuanwu Lake business district [2] - The city leadership highlights the need for collaboration between urban and suburban areas to leverage local advantages and enhance industrial transformation [3]

Core Insights - The global health food revolution is significantly linked to corn, with rising health awareness driving consumers to reduce sugar intake and opt for sugar substitutes like erythritol [1][2] - The erythritol market is projected to reach approximately $910 million in 2024, with China dominating the market at a 73% share, highlighting its central role in the global supply chain [1] - Dongxiao Biotechnology Co., Ltd. is emerging as a key player in China's biotech sector, leveraging advanced corn processing technology and automation to produce high-value products [1][2] Company Overview - Dongxiao Biotechnology operates a fully integrated value chain, converting corn into various high-value products, including starch sugars, erythritol, and amino acids, through precise fermentation and extraction processes [2] - The company has an annual corn processing capacity of 1.7 million tons, enabling it to maximize the value derived from each corn kernel [2] - The production process includes advanced membrane separation and purification techniques, resulting in erythritol with a purity of over 99.5% [2] Product Advantages - Erythritol is favored by many well-known brands due to its natural origin and safety, being the only natural sweetener recognized as having no daily intake limit by various health authorities [3] - Its unique properties, such as zero calories, non-participation in blood sugar metabolism, and high tolerance, make it suitable for a wide range of applications in food, health products, cosmetics, and pharmaceuticals [3] Technological Innovation - Dongxiao Biotechnology has invested heavily in R&D, employing a team of nearly 200 professionals, including academicians and PhDs, to drive innovation in synthetic biology and fermentation technology [4] - The company has optimized its fermentation process, reducing the fermentation cycle by 25% and increasing conversion rates by 5%, while also lowering energy consumption by 15% [5] Future Developments - The company is positioning itself for the next generation of natural sweeteners, specifically allulose, which has a sweetness level similar to sucrose but only 10% of its calories [6] - Allulose has been approved as a new food ingredient in China and is expected to be widely used in various food products, including baked goods and beverages [6] - Dongxiao Biotechnology aims to expand its product offerings in functional products, probiotics, functional amino acids, rare sugars, and biodegradable materials, enhancing its value chain in the health industry [6]

Core Insights - The global health food revolution is significantly linked to corn, with a rising demand for sugar alternatives driven by health consciousness and weight management needs [1] - The global erythritol market is projected to reach approximately $910 million in 2024, with China dominating the market with a 73% share [1] - Dongxiao Biotechnology Co., Ltd. is emerging as a key player in China's biotechnology sector, leveraging advanced corn deep processing technology and automation [1] Company Overview - Dongxiao Biotechnology operates a fully integrated value chain, converting corn into high-value products such as starch sugars, erythritol, and amino acids through precise fermentation and extraction processes [2] - The company has an annual corn processing capacity of 1.7 million tons, enabling it to produce a wide range of products, enhancing resource utilization efficiency and establishing a circular economy [2] Product Advantages - Erythritol is favored by many well-known brands due to its natural and safe profile, being the only natural sweetener recognized as having no daily intake limit by health authorities [3] - The safety of erythritol has been validated by organizations such as WHO and FDA, making it widely applicable in food, health products, cosmetics, and pharmaceuticals [3] Technological Innovation - Dongxiao Biotechnology has invested in a robust R&D team of nearly 200 members, focusing on synthetic biology and fermentation technology to enhance production efficiency [4][5] - The company has achieved a 25% reduction in fermentation cycle time and a 15% decrease in energy consumption through proprietary technologies, promoting green manufacturing practices [5] Future Developments - The company is strategically positioning itself in the next generation of natural sweeteners, specifically allulose, which has a sweetness level similar to sucrose but with significantly lower calories [6] - Dongxiao Biotechnology aims to expand its functional product offerings, including probiotics, functional amino acids, rare functional sugars, and biodegradable materials, to enhance the health industry value chain [6]

Core Viewpoint - The company Jia Bi You announced the termination of its acquisition of 63.21% equity in Ou Yi Biological after nearly 10 months of planning, citing changes in the external market environment as the reason for this cautious decision [2][6]. Summary by Sections Termination Reasons - Jia Bi You's latest announcement indicated that the termination of the acquisition was due to the failure to reach an agreement on core transaction terms, and the company has withdrawn its application documents [4][6]. Background of the Acquisition - Since October 29 of the previous year, Jia Bi You had been planning a major asset restructuring, initially aiming to acquire 65% of Ou Yi Biological's equity. This was later adjusted to 63.21% and involved a reduction in the number of transaction parties from 14 to 13 [7][8]. - The adjusted proposal included issuing 29.77 million shares at a price of 19.29 yuan per share, totaling a transaction price of 830.6 million yuan, which would have resulted in a significant goodwill addition of 721 million yuan, accounting for 43.3% of total assets and 47.21% of net assets as of September 30, 2024 [7][8]. Financial Performance - In the first half of the year, Jia Bi You reported a revenue of 307 million yuan, representing a year-on-year increase of 17.6%, and a net profit attributable to shareholders of 108 million yuan, reflecting a growth of 59.01% [8].